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The current COVID-19 pandemic created a significant 
challenge for all human life aspects including the health 
sector. One of the most important challenges was how to 
find treatment for the disease. Till now, a long list of 
pharmaceuticals has been tested; mostly disappointing. 
However, the virus' incursion continues (1). 
All the currently available pharmaceuticals used 
for the treatment of COVID-19 are repurposed ones (2); 
while, none have been promising yet and emerging drugs 
are inevitable. Molecular docking is a shortcut to the 
discovery of emerging repurposed drugs (3). In this issue 
of the Journal of Cellular and Molecular Anesthesia, 
Saidijam et al. have proposed three main SARSCoV-2 
NTPase/Helicase inhibitors as potential pharmaceuticals 
for the treatment of COVID-19, using molecular docking 
and dynamics simulation approach (4). These three 
phenolic compounds (i.e. amentoflavone, theaflavin 3'-
gallate, and procyanidin) have been discovered from a 
long list of 52 phenolic compounds (mostly flavonoids) 
using a drug discovery method (i.e. a molecular docking) 
to analyze their binding affinity to SARS-CoV-2 
NTPase/helicase. 
There are some Pro and Con viewpoints regarding 
such drug discovery techniques. One of them is that in 
such studies no clinical or preclinical studies are needed 
to discover these compounds since the methodology of 
the study is a fast-track shortcut to find the potential 
pharmaceuticals in emergent cases like COVID-19. 
Besides, these potential therapies have been emerged 
using bioinformatics prediction models and molecular 
docking approaches with a relatively sound and logical 
rationale. On the other hand, these compounds defect 
proofs and need trials to be documented as therapeutic 
agents. 
The COVID-19 era has ruled us through paths that 
were not well experienced. COVID-19 has taught us new 
paradigms not learned before; in other words, we are 
learning a paradigm shift in our medicine; however, a 
long path is ahead of us and many other new lessons 
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